ArticleBMC infectious diseases2025
Characteristics of Klebsiella pneumoniae and carbapenem-resistant Klebsiella pneumoniae clinical isolates from COVID-19 patients: a single-center retrospective analysis in a tertiary hospital, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular and phenotypic profiles of carbapenem- and third-generation cephalosporin-resistant Klebsiella pneumoniae isolates from the fecal microbiota of pediatric patients with COVID-19.BMC microbiology · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review.Infectious diseases and therapy · 2026Review
- Clinical risk factors and genomic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Plasmid-associated clonal expansion drives department-preference transmission of carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic has exacerbated the complexity of antimicrobial resistance (AMR) challenges. This study aimed to quantify risk factors for carbapenem-resistant Klebsiella pneumoniae (CRKP) acquisition in COVID-19 patients, compare resistance profiles and laboratory biomarkers between carbapenem-susceptible K. pneumoniae (CS-KP) and CRKP strains, and identify clinical indicators predictive of CRKP co-infection.
methodsWe conducted a retrospective analysis of COVID-19 patients with KP-positive cultures admitted to a tertiary hospital in China between January 2020 and May 2024. Antimicrobial susceptibility testing and multivariable logistic regression were employed to evaluate resistance patterns and risk factors.
resultsAmong 342 COVID-19 patients with KP-positive, 262 (76.6%) were CSKP and 80 (23.4%) CRKP. Hypertension, prolonged hospitalization, and ICU admission were identified as independent risk factors for CRKP acquisition. CRKP group patients exhibited significantly worse laboratory tests, including elevated inflammatory markers, coagulopathy, and renal dysfunction, providing clinical markers for suspecting the presence of multi-drug resistant bacteria.
conclusionsOur findings reveal KP resistance profiles under COVID-19 pressures and underscore the necessity of early microbiological confirmation and precision antibiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.